The antibiotic minocycline increases the lifespan of aged roundworms and prevents the buildup of proteins, revealing a protective mechanism that could be exploited therapeutically to help prevent neurodegenerative diseases.
Now, scientists at Scripps Research have found that minocycline can increase the lifespan of roundworms by preventing the buildup of proteins during aging, according to a study in the open-access journal eLife reports.
Protein aggregation causes several progressive age-related brain diseases, including amyotrophic lateral sclerosis, Alzheimer’s, Parkinson’s and prion diseases. The Scripps Research study shows that minocycline prevents this buildup even in older animals with age-impaired stress-response pathways.
The number of proteins in a cell is balanced by the rate of protein manufacture and disposal, called proteostasis. As we age, proteostasis becomes impaired.
“It would be great if there were a way to enhance proteostasis and extend lifespan and health, by treating older people at the first sign of neurodegenerative symptoms or disease markers such as protein build-up,” says lead author Gregory Solis, a graduate student at Scripps Research. “In this study, we investigated whether minocycline can reduce protein aggregation and extend lifespan in animals that already have impaired proteostasis.”
The team first tested 21 different molecules known to extend lifespan in young and old Caenorhabditis elegans (C. elegans) worms. They found that all of these molecules prolonged the lives of young worms, however, the only drug that worked on the older worms was minocycline.
To find out why, the researchers looked at whether minocycline had any effect on protein aggregation in the worms. They treated young and old worms with water or minocycline and then measured two proteins, ?-synuclein and amyloid-?, which are known to build up in Parkinson’s and Alzheimer’s, respectively. Regardless of the worms’ age, those treated with minocycline had reduced aggregation of both proteins as they grew older.
The team next turned their attention to the mechanism behind this discovery. First, they looked at whether minocycline switches on stress-signaling proteins that are impaired in older worms, but they found the drug actually reduces their activity. Next, they studied whether it turns off the cell’s protein-disposal processes, but this was not its mode of action either.
When researchers used a chemical probe to see how minocycline affects the major protein-regulating molecules in the cell, it revealed that minocycline directly affects the protein-manufacturing machinery of the cell, known as the ribosome. This was true in worms, as well as in mouse and human cells.
Finally, the team used worms with increased or decreased protein-manufacturing activity and studied how this altered the effect of minocycline on protein levels and lifespan. As predicted, in mutant worms where protein manufacturing was already decreased, they found a lower dose of minocycline was needed to further reduce protein levels and extend lifespan. In worms where protein manufacturing was increased, the opposite was seen. This suggested that minocycline extends lifespan by controlling the rate of protein manufacturing at the ribosome.
“We have identified minocycline as a drug that can extend lifespan and improve protein balance in already-aging worms,” says Michael Petrascheck, PhD, senior author of the paper and associate professor at Scripps Research. “Our study reveals how minocycline prevents protein aggregation and lays the foundations for drug development efforts aimed at optimizing this already-approved drug for a range of neurodegenerative diseases.”
The Latest on: Minocycline
via Google News
The Latest on: Minocycline
- Alzheimer's Trial: Lessons From a Failed Drugon November 18, 2019 at 8:30 pm
Minocycline (Minocin), an anti-inflammatory tetracycline that crosses the blood-brain barrier and inhibits proinflammatory microglia, did not improve cognitive or functional performance in people with ...
- Foamix Announces Enrollment Completion of Phase 2 Acne Clinical Trial for FCD105 Minocycline 3% and Adapalene 0.3% Combination Foamon November 18, 2019 at 4:17 pm
The trial will evaluate the efficacy and safety of the investigational topical combination foam, which comprises minocycline 3% and adapalene 0.3%. "We are truly grateful to participants, caregivers ...
- Foamix Reports Third Quarter 2019 Financial Results and Provides Corporate Updateon November 11, 2019 at 2:00 am
AMZEEQ is the first FDA approved topical form of minocycline and its approval represents a significant step in our goal of enhancing the standard of care for acne sufferers in the U.S.,” said David ...
- Foamix Announces Publication of AMZEEQ™ (minocycline) Topical Foam Long Term Safety Data for Treatment Up to 1 Year in Journalon November 5, 2019 at 4:52 am
Before it's here, it's on the Bloomberg Terminal.
- The FDA Just Approved the First-Ever Topical Minocycline for Acneon October 28, 2019 at 10:16 am
As someone with acne-prone skin, the crux of my skin-care routine isn't luxurious cleansers or innovative pimple pads. In fact, the most important step of my skin-care routine happens far away from ...
- The FDA Just Approved the First-Ever Topical Minocycline for Acneon October 28, 2019 at 9:59 am
Last week, the FDA announced the approval of Amzeeq, a topical form of the antiobiotic minocycline. Until now, minocycline has only been available as an oral antibiotic. Amzeeq, a product of parent ...
- Foamix enters commercial supply agreement for topical foam antibioticon October 24, 2019 at 8:29 am
Amzeeq (minocycline) topical foam was approved by the US Food and Drug Administration (FDA) last week for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. Upon ...
- FDA approves minocycline topical foam for acneon October 22, 2019 at 7:15 am
Linda Stein Gold "Amzeeq topical minocycline foam 4% offers a novel treatment of acne which is effective and well tolerated," Linda Stein Gold, MD, director of dermatology clinical research at Henry ...
- FDA Clears First Topical Form of Minocycline for Acneon October 21, 2019 at 1:48 pm
The US Food and Drug Administration (FDA) has approved 4% minocycline topical foam (Amzeeq, Foamix Pharmaceuticals) to treat inflammatory lesions of nonnodular moderate to severe acne vulgaris in ...
- FDA Approves Minocycline Topical Foam for Acne Vulgarison October 21, 2019 at 7:41 am
Officials with the FDA have approved minocycline (Amzeeq, Foamix) topical foam, 4% for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in adults and pediatric ...
via Bing News